Last reviewed · How we verify
Half-boosted Fosamprenavir
Half-boosted fosamprenavir is an HIV protease inhibitor that blocks viral protease enzyme activity with reduced ritonavir boosting compared to standard fosamprenavir formulations.
Half-boosted fosamprenavir is an HIV protease inhibitor that blocks viral protease enzyme activity with reduced ritonavir boosting compared to standard fosamprenavir formulations. Used for HIV-1 infection in treatment-naïve or treatment-experienced patients.
At a glance
| Generic name | Half-boosted Fosamprenavir |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | HIV protease inhibitor |
| Target | HIV protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Fosamprenavir is a prodrug of amprenavir that inhibits HIV protease, preventing the cleavage of viral polyproteins necessary for viral maturation and infectivity. The 'half-boosted' designation indicates a reduced dose of ritonavir (a CYP3A4 inhibitor) is used to enhance fosamprenavir plasma concentrations, potentially improving tolerability while maintaining antiviral efficacy.
Approved indications
- HIV-1 infection in treatment-naïve or treatment-experienced patients
Common side effects
- Diarrhea
- Nausea
- Rash
- Headache
- Elevated transaminases
Key clinical trials
- A Study of an Investigational Regimen Combining FDA Approved HIV Drugs in HIV-Infected Subjects (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Half-boosted Fosamprenavir CI brief — competitive landscape report
- Half-boosted Fosamprenavir updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI